Literature DB >> 11060472

Pathophysiology and pharmacological treatment of gastroesophageal reflux disease.

M Storr1, A Meining, H D Allescher.   

Abstract

Gastroesophageal reflux disease (GERD) is one of the most common diagnoses in a gastroenterologist's practice. Gastroesophageal reflux describes the retrograde movement of gastric contents through the lower esophageal sphincter (LES) to the esophagus. It is a common, normal phenomenon which may occur with or without accompanying symptoms. Symptoms associated with GERD include heartburn, acid regurgitation, noncardiac chest pain, dysphagia, globus pharyngitis, chronic cough, asthma, hoarseness, laryngitis, chronic sinusitis and dental erosions. The introduction of fiberoptic instruments and ambulatory devices for continuous monitoring of esophageal pH (24-hour pH monitoring) has led to great improvement in the ability to diagnose reflux disease and reflux-associated complications. The development of pathological reflux and GERD can be attributed to many factors. Pathophysiology of GERD includes incompetent LES because of a decreased LES pressure, transient lower esophageal sphincter relaxations (TLESRs) and deficient or delayed esophageal acid clearance. Uncomplicated GER may be treated by modification of life style and eating habits in an early stage of GERD. The various agents currently used for treatment of GERD include mucoprotective substances, antacids, H(2) blockers, prokinetics and proton pump inhibitors. Although these drugs are effective, they do not necessarily influence the underlying causes of the disease by improving the esophageal clearance, increasing the LESP or reducing the frequency of TLESRs. The following article gives an overview regarding current concepts of the pathophysiology and pharmacological treatment of GERD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060472     DOI: 10.1159/000016970

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

1.  Esophagitis impairs esophageal smooth muscle reactivity in the rat model: an in vitro study.

Authors:  Melih Tugay; Firuzan Yildiz; Tijen Utkan; Bahar Müezzinoğlu; Faruk Erden; Nejat Gacar; Güner Ulak
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

2.  Effect of fasting on laryngopharyngeal reflux disease in male subjects.

Authors:  Abdul-latif Hamdan; Jihad Nassar; Alexander Dowli; Zeid Al Zaghal; Alain Sabri
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-11       Impact factor: 2.503

3.  Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.

Authors:  Peter J Kahrilas; Philip Miner; John Johanson; Lian Mao; Leonard Jokubaitis; Sheldon Sloan
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 4.  Gastro-oesophageal reflux and bronchial asthma: current status and future directions.

Authors:  J L Mathew; M Singh; S K Mittal
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

Review 5.  Gastric function measurements in drug development.

Authors:  Thorsten Pohle; Wolfram Domschke
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 6.  Pathophysiology of gastro-oesophageal reflux disease.

Authors:  F De Giorgi; M Palmiero; I Esposito; F Mosca; R Cuomo
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

7.  The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients With Hypertension.

Authors:  Zhi-Tong Li; Feng Ji; Xin-Wei Han; Li Wang; Yong-Qiang Yue; Zhong-Gao Wang
Journal:  J Clin Gastroenterol       Date:  2018-09       Impact factor: 3.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.